LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

Home・Aktien・AbbVie Inc

AbbVie Inc

Geschlossen

BrancheGesundheitswesen

210.82 1.12

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

207.65

Max

213.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.1B 697M
Verkäufe	-1.6B 15B
KGV Branchendurchschnitt	99.402 51.415
EPS	2.65
Dividendenrendite	3.34
Gewinnspanne	4.646
Angestellte	57,000
EBITDA	-635M 4.7B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+21.9% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	3.34% 2.34%
Nächstes Ergebnis	30. Juli 2026
Nächste Dividendenausschüttung	15. Mai 2026
Nächstes Ex-Dividendendatum	14. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	9.2B 358B
Vorheriger Eröffnungskurs	209.7
Vorheriger Schlusskurs	210.82

Nachrichtenstimmung

By Acuity

18%

82%

36 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

180.37 / 195.54 Unterstützung & Widerstand

AbbVie Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

AbbVie Inc Prognose

Kursziel

By TipRanks

21.9% Vorteil

12-Monats-Prognose

Durchschnitt 254.17 USD 21.9%

Hoch 298 USD

Tief 203 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AbbVie Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

Buy

Halten

Sell

Basierend auf 20 Analysten, die in den letzten 3 Monaten Aktienbewertungen für AbbVie Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

180.37 / 195.54Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Stimmung

By Acuity

36 / 346 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.